Design Sustained Release Bi-Layer Tablet of Antihypertensive Drug for Improved Drug Delivery

The aim of present study is to design sustained release Bilayer tablet of Antihypertensive drug for improved drug delivery. To develop stable formulation of Antihypertensive drugs. To develop improved beneficial technology to overcome the shortcoming of the single tablet. To design modified release drug product for optimization of therapeutic regimen. To ensure safety and to improve efficacy of drug as well as patient compliance. To study the effect of concentration of polymer on drug release. Evaluation of precompression parameters such as angle of repose, bulk density, tapped density. The oral route is the most popular route used for administration of drugs, which is due in part to the ease of administration and to the fact that gastrointestinal physiology offers more flexibility in dosage form design than most other routes1. The term sustained release, prolonged release, modified release, extended release, or depot formulation are used to identify drugs delivery systems that are designed to achieve or extended therapeutic effect by continuously releasing medication over an extended period of time after administration of a single dose. Bilayer tablets can be primary option to avoid chemical incompatibilities between APIs by physical separation and to enable the development of different drug release profiles. Bilayer tablet is suitable for sequential release of two drugs in combination and also for sustained release of tablet in which one layer is for immediate release as loading dose and second layer is maintenance dose. So use of bilayer tablets is a very different aspect for antihypertensive, diabetic, antiinflammatory and analgesic drugs where combination therapy is often used. Several pharmaceutical companies are currently developing bilayer tablets, for a variety of reasons: patent extension, therapeutic, marketing to name a few. Generally, tablets manufacturing principles remain the same, there is much more to consider because making multilayer tablets involves multiple often incompatible products, additional equipment and many formulation and operation challenges.